US · ALNY
Alnylam Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- alnylam.com
Price · as of 2025-12-31
$296.11
Market cap 44.15B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $849.16 | +186.77% |
| Intrinsic Value(DCF) | $21,567.23 | +7,183.52% |
| Graham-Dodd Method(GD) | $18.00 | -93.92% |
| Graham Formula(GF) | $168.83 | -42.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $12.18 | $27.07 | $0.74 | $0.00 | $11.31 |
| 2012 | $24.58 | $28.86 | $0.00 | $0.00 | $21.98 |
| 2013 | $73.12 | $54.21 | $2.31 | $0.00 | $28.98 |
| 2014 | $113.57 | $55.57 | $5.61 | $0.00 | $0.00 |
| 2015 | $62.15 | $45.31 | $10.20 | $0.00 | $34.02 |
| 2016 | $50.73 | $29.95 | $4.48 | $0.00 | $0.00 |
| 2017 | $133.02 | $71.17 | $12.37 | $0.00 | $0.00 |
| 2018 | $83.27 | $40.92 | $3.72 | $0.00 | $58.65 |
| 2019 | $113.39 | $64.68 | $1,484.22 | $0.00 | $0.00 |
| 2020 | $142.20 | $69.51 | $3,200.88 | $0.00 | $0.00 |
| 2021 | $154.96 | $72.27 | $52,656.85 | $0.00 | $0.00 |
| 2022 | $182.66 | $79.91 | $1,369.89 | $0.00 | $0.00 |
| 2023 | $149.82 | $89.08 | $10,551.52 | $0.00 | $0.00 |
| 2024 | $244.52 | $125.21 | $1,491.24 | $0.00 | $0.00 |
| 2025 | $325.07 | $849.16 | $7,605.01 | $18.00 | $168.83 |
AI valuation
Our deep-learning model estimates Alnylam Pharmaceuticals, Inc.'s (ALNY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $849.16
- Current price
- $296.11
- AI upside
- +186.77%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$21,567.23
+7,183.52% upside
Graham-Dodd
$18.00
-93.92% upside
Graham Formula
$168.83
-42.98% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALNY | Alnylam Pharmaceuticals, … | $296.11 | 44.15B | +187% | +7,184% | -94% | -43% | 135.73 | 53.96 | 11.47 | 73.50 | — | 53.96 | 81.77% | 13.51% | 8.45% | 73.28% | -134.35% | 6.82% | 1.62 | 1.99 | 2.76 | 2.51 | -0.68 | -20688.00% | 6519.00% | -119273.00% | 1.09% | 0.36 | -128.40% | 0.00% | 0.00% | 5.06% | 81.65 | 88.00 | 11.03 | 5.93 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| CI | Cigna Corporation | $289.82 | 77.42B | -21% | +327% | -97% | +46% | 12.30 | 1.85 | 0.28 | 8.71 | 14.84 | -2.43 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 8292.00% | 1126.00% | -634.00% | 10.85% | 0.17 | 12.88% | 2.08% | 25.60% | 7.58% | 11.08 | 12.06 | 0.37 | 2.69 |
| COR | Cencora, Inc. | $372.14 | 72.39B | -33% | -64% | — | -63% | 41.92 | 43.58 | 0.20 | 19.29 | 734.06 | -4.12 | 3.16% | 1.14% | 0.48% | 145.58% | 42.46% | 2.18% | 7.13 | 8.69 | 0.90 | 0.51 | 1.70 | 571.00% | 931.00% | 699.00% | 4.88% | 0.07 | 53.77% | 0.67% | 27.90% | 1.33% | 19.76 | 22.47 | 0.22 | 4.91 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| IDXX | IDEXX Laboratories, Inc. | $656.73 | 52.44B | -34% | -40% | -88% | -64% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| REGN | Regeneron Pharmaceuticals… | $781.67 | 81.22B | -37% | -58% | -41% | -50% | 18.36 | 2.65 | 5.77 | 13.20 | 224.20 | 2.76 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 819.00% | 99.00% | 1135.00% | 4.93% | 1.14 | 16.86% | 0.45% | 8.20% | 5.36% | 21.47 | 18.83 | 5.36 | 7.62 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- CEO
- Yvonne L. Greenstreet
- Employees
- 2.23K
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($21,567.23 ÷ $296.11) − 1 = +7,183.52% (DCF, example).